Insider Trader Watch: Aralez Pharmaceuticals Inc. $ARLZ

46f6694f00f8e1581cf2ace674ed04f3

Aralez Pharmaceuticals Inc. (ARLZ) insider have most recently took part in a trading activity. On Jun 15, 2017 Kirsch Arthur S, Director bought 15,000 shares having total worth of $17,250 at the price of $1.15 per share, following the transaction a total of 226,609 shares owned by Kirsch Arthur S. Before this latest buy, Kirsch Arthur S purchased ARLZ at 2 other times during the past twelve months, for a total investment of $160,650 at an average of $1.72 per share.

The stock has experienced a total of 5 insider trades in the past three months. These trades include 4 sell activities and 1 buy trades. Furthermore, over the past 12 months , the stock was traded 16 times by insiders. In 6 of these trades, the insider was a seller while an employee of the company was the buyer in 10 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 1 4 -71.12%
12 Month 10 6 -81.15%

Shares of Aralez Pharmaceuticals Inc. (ARLZ) traded up 5.22% on Jun 16, 2017, hitting $1.21. 575,728 shares of the company’s stock traded hands. Aralez Pharmaceuticals Inc. has a 52 week low of $1.14 and a 52 week high of $6.71. The company’s market cap is $316 million.

Aralez Pharmaceuticals Inc. (ARLZ) last announced its earnings results on May 9, 2017. The company reported -0.42 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.40 by $0.02. The company had revenue of $26 million for the quarter, compared to the consensus estimate of $21 million. During the same quarter in the previous year, the company posted -0.73 earnings per share. The company’s revenue for the quarter was up 222% on a year-over-year basis.

2017-05-09 2017-03-13 2016-11-07 2016-08-09 2016-03-15
earnings per share -0.42 -0.40 -0.32 -0.27 -0.40
Revenue(M) 25.97 20.01 13.63 12.58 5.97

POZEN Inc., is incorporated in the state of Delaware on September 25, 1996. It operates as a pharmaceutical company focused on developing products which could provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. The Company has developed Treximet in collaboration with GlaxoSmithKline. Treximet is the brand name for the product combining sumatriptan 85 mg, formulated with RT Technology and naproxen sodium 500 mg in a single tablet designed for the acute treatment of migraine. Treximet incorporates its MT 400 technology, which refers to its proprietary combinations of a triptan (5-HT1B/1D agonist) and a non-steroidal anti-inflammatory drug, or NSAID. Under its MT 400 technology, it seeks to develop product candidates that provide acute migraine therapy by combining the activity of two drugs that act by different mechanisms to reduce the pain and associated symptoms of migraine. It is developing product candidates that combine a type of acid inhibitor, a proton pump inhibitor, with an NSAID. These product candidates plan to provide management of pain and inflammations associated with conditions such as osteoarthritis, and are intended to have fewer gastrointestinal complications compared to an NSAID taken alone. It has also developed VIMOVO with AstraZeneca AB, or AstraZeneca. VIMOVO (formerly referred to as PN 400) is the brand name for a proprietary fixed dose combination of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet. On April 30, 2010, the FDA approved VIMOVO for the relief of the signs and symptoms of osteoarthritis (“OA”), rheumatoid arthritis (“RA”) and ankylosing spondylitis (“AS”) and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. The competition for VIMOVO comes from the oral anti-arthritic market, or more specifically the traditional non-selective NSAIDs (such as naproxen and diclofenac), traditional NSAID/gastroprotective agent combination products or combination product packages (such as Arthrotec and Prevacid NapraPACTM ) and the only remaining COX-2 inhibitor, Celebrex. Therapeutic product candidates for human use are subject to rigorous preclinical and clinical testing and other requirements of the Federal Food, Drug and Cosmetic Act, or FFDCA, implemented by the FDA, as well as similar statutory and regulatory requirements of foreign countries.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.